Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 8/20 | 0.39 |
| ▸ | MAOA | P21397 | 7/20 | 0.39 |
| ▸ | KDM1A | O60341 | 5/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL779656 | 0.82 | ALDH1A1 (0.38) | SLC18A3SIGMAR1TSHRMAOBMAOA | |
| SCHEMBL2160450 | 0.80 | ALDH1A1 (0.41) | SLC18A3SIGMAR1TSHRCYP1A2CYP2D6 | |
| SCHEMBL2157992 | 0.80 | ALDH1A1 (0.41) | SLC18A3SIGMAR1TSHRCYP1A2CYP2D6 | |
| SCHEMBL777693 | 0.80 | ALDH1A1 (0.41) | SLC18A3SIGMAR1TSHRCYP1A2CYP2D6 | |
| SCHEMBL11484818 | 0.79 | SLC18A3 (0.40) | SLC18A3SIGMAR1ALDH1A1GAA | |
| SCHEMBL1199949 | 0.77 | CYP2C19 (0.41) | SLC18A3SIGMAR1TSHRMAOBMAOA | |
| SCHEMBL20561348 | 0.77 | CYP2C19 (0.41) | SLC18A3SIGMAR1TSHRMAOBMAOA | |
| SCHEMBL779950 | 0.77 | AKR1C3 (0.44) | SLC18A3SIGMAR1MAOBMAOAKDM1A | |
| SCHEMBL303054 | 0.77 | — | — | |
| SCHEMBL2103232 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108137542-B | Pyridone dicarboxamides as bromodomain inhibitors | 葛兰素史克知识产权第二有限公司 | 2023-10-27 | — | — | CN | disclosed |
| EP-3798217-B1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-02-22 | — | — | EP | disclosed |
| CN-110563717-B | Piperidine CXCR7 receptor modulators | 爱杜西亚药品有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-109563085-B | Piperidine CXCR7 receptor modulators | 爱杜西亚药品有限公司 | 2022-08-09 | — | — | CN | disclosed |
| EP-3490986-B1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-11-24 | — | — | EP | disclosed |
| EP-3863711-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2021-08-18 | — | — | EP | disclosed |
| EP-3798217-A1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2021-03-31 | — | — | EP | disclosed |
| US-10927080-B2 | Pyridinone dicarboxamide for use as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2021-02-23 | — | — | US | disclosed |
| US-20200385373-A1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-12-10 | — | — | US | disclosed |
| US-10752620-B2 | Piperdine CXCR7 receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2020-08-25 | — | — | US | disclosed |
| EP-1142882-A9 | ACRYLONITRILE COMPOUNDS | Nissan Chemical Industries, Ltd. (JP) | 2002-10-02 | — | — | EP | disclosed |
| EP-1235808-A2 | TRICYCLIC ANALGESICS | WARNER-LAMBERT COMPANY (US) | 2002-09-04 | — | — | EP | disclosed |
| WO-2002000647-A1 | HETEROARYL-PHENYL SUBSTITUTED FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-01-03 | — | — | WO | disclosed |
| EP-1142882-A1 | ACRYLONITRILE COMPOUNDS | Nissan Chemical Industries, Ltd. (JP) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000075116-A2 | TRICYCLIC ANALGESICS | WARNER-LAMBERT COMPANY (US) | 2000-12-14 | — | — | WO | disclosed |
| US-6063734-A | AGRICULTURAL CHEMICALS, AGENTS FOR PREVENTING ATTACHMENT OF AQUATIC ORGANISMS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2000-05-16 | — | — | US | disclosed |
| US-6020426-A | BLOCK OR GRAFT COPOLYMER | FUJI XEROX CO., LTD. (JP) | 2000-02-01 | — | — | US | disclosed |
| EP-0913392-A1 | ETHYLENE DERIVATIVES AND PEST CONTROLLING AGENTS | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1999-05-06 | — | — | EP | disclosed |
| US-5877370-A | Method for minimizing diarylalkane formation in alkylation of aromatics by olefins by zeolite beta | UOP LLC (US) | 1999-03-02 | — | — | US | disclosed |
| US-5258513-A | FOR TREATMENT OF ALZHEIMER'S DISEASE, SENILE DEMENTIA, EVOLUTIVE COGNITIVE PATHOLOGIES, DEPRESSION, ANXIETY, MOOD DISTURBANCES, INFLAMMATION AND ASTHMA | UCB S.A. (BE) | 1993-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200385373-A1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | CXCR1, CXCR5, ACKR3 | SLC18A3 2759/4885SIGMAR1 254/4885TSHR 246/4885 |
| US-10927080-B2 | Pyridinone dicarboxamide for use as bromodomain inhibitors | BRD4, BRD3, BRDT | SLC18A3 2317/4885SIGMAR1 3261/4885TSHR 2687/4885 |
| US-10752620-B2 | Piperdine CXCR7 receptor modulators | CXCR1, CXCR5, ACKR3 | SLC18A3 2480/4885SIGMAR1 218/4885TSHR 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.